Acucela Inc.

Revision Therapeutics, Inc.

Sirion Therapeutics, Inc.

Nathan L Mata

Jay Lichter

Kenneth J Widder

Mustapha Haddach

Kim B Phan

Tam V Bui

Natalia Tsivkovskaia

Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.

Methods and compositions for treating ophthalmic conditions with retinyl derivatives

Compounds that reduce serum retinol levels are used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods, compounds, and compositions to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions.

Methods and compounds for treating retinol-related diseases

Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.

Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation

Growing community of inventors

La Jolla, CA, United States of America

Nathan L Mata